<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04621201</url>
  </required_header>
  <id_info>
    <org_study_id>SAR-GEN_ITA</org_study_id>
    <nct_id>NCT04621201</nct_id>
  </id_info>
  <brief_title>Genomic Profiles Analysis in Children, Adolescents and Young Adult With Sarcomas</brief_title>
  <official_title>Genomic Profiles Analysis in Children, Adolescents and Young Adult With Sarcomas (SAR-GEN_ITA): a Multicenter Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Associazione Italiana Ematologia Oncologia Pediatrica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bone and soft tissue sarcomas represent about 7-12% of all pediatric cancer and are a&#xD;
      heterogeneous group of tumors arising in connective tissues embryologically derived from the&#xD;
      mesenchyme. For some of these tumors relapse and mortality rates are still significantly&#xD;
      high. Therefore, further studies are needed to better understand pathogenetic processes&#xD;
      underlying sarcomas to offer new and more effective treatments. Next generation sequencing&#xD;
      (NGS) has opened new frontiers for cancer research allowing to identify somatic or&#xD;
      constitutional mutations known or yet unknown with the aim to better understand&#xD;
      carcinogenesis. The establishment of the genomic profile of the tumor could also help&#xD;
      clinicians to personalize patients treatment based on their genetic and molecular&#xD;
      alterations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 6, 2018</start_date>
  <completion_date type="Anticipated">December 6, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 6, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>evaluate the genomic profiles of osteosarcoma, Ewing sarcoma and Synovial Sarcoma tumor samples in pediatric, adolescents and young adult patients at the time of diagnosis or relapse/progression</measure>
    <time_frame>2018-2021</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Diagnosed or Relapsed/Refractory Sarcomas</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>observation and biopsy</intervention_name>
    <description>biopsy</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      biopsies&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children, adolescents and young adults aged ≤ 24 years with newly diagnosed or&#xD;
        relapsed/refractory Osteosarcoma, Ewing Sarcoma or Synovial Sarcoma.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with histologically confirmed Osteosarcoma, Ewing Sarcoma or Synovial Sarcoma&#xD;
             at first diagnosis.&#xD;
&#xD;
          2. Patients with confirmed relapsed/refractory Osteosarcoma, Ewing Sarcoma or Synovial&#xD;
             Sarcoma&#xD;
&#xD;
          3. Written informed consent signed by the patient, or parents or legal representative to&#xD;
             perform molecular analysis of the tumor sample.&#xD;
&#xD;
          4. Patients aged ≤24 years&#xD;
&#xD;
          5. Pathological review of tumor samples.&#xD;
&#xD;
          6. Availability of fresh tumor sample from newly diagnosed or relapsed/refractory cancer&#xD;
             and 10 ml of EDTA peripheral blood sample. Centralization of paraffin-embedded tumor&#xD;
             sample might be optional.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Known history of active HIV, HCV, or HBV infection 2. Presence of a condition or&#xD;
             abnormality that in the opinion of the Investigator would compromise the safety of the&#xD;
             patient undergoing surgery biopsy or the quality of the data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franca Fagioli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AOU Città della Salute e della Scienza di Torino</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisa Tirtei, MD</last_name>
    <phone>00390113135171</phone>
    <email>etirtei@cittadellasalute.to.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Celeste Cagnazzo, PhD</last_name>
    <email>celeste.cagnazzo@unito.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AOU Città della Salute e della Scienza di Torino - Presidio Infantile Regina Margherita</name>
      <address>
        <city>Torino</city>
        <state>Turin</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celeste Cagnazzo, PhD</last_name>
      <phone>00390113135171</phone>
      <email>celeste.cagnazzo@unito.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>December 2, 2020</last_update_submitted>
  <last_update_submitted_qc>December 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna</investigator_affiliation>
    <investigator_full_name>Prof. Franca Fagioli</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

